Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Weight Management Benefit for Pediatric Members
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PMN.305 alerts
Get alerted when Policy MDN.CP.PMN.305 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) when requested for chronic weight management in pediatric members through the EPSDT benefit; applies to Meridian Medicaid lines of business.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.